Insider Selling: Establishment Labs (NASDAQ:ESTA) Director Sells $144,446.80 in Stock

Establishment Labs Holdings Inc. (NASDAQ:ESTA) Director Quiros Juan Jose Chacon sold 2,180 shares of the firm’s stock in a transaction that occurred on Monday, April 27th. The stock was sold at an average price of $66.26, for a total value of $144,446.80. Following the transaction, the director owned 1,107,504 shares of the company’s stock, valued at $73,383,215.04. This trade represents a 0.20% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink.

Quiros Juan Jose Chacon also recently made the following trade(s):

• On Friday, April 24th, Quiros Juan Jose Chacon sold 30,178 shares of Establishment Labs stock. The stock was sold at an average price of $65.78, for a total value of $1,985,108.84.
• On Thursday, April 23rd, Quiros Juan Jose Chacon sold 42,642 shares of Establishment Labs stock. The stock was sold at an average price of $65.43, for a total value of $2,790,066.06.
• On Tuesday, April 14th, Quiros Juan Jose Chacon sold 37,500 shares of Establishment Labs stock. The stock was sold at an average price of $65.23, for a total value of $2,446,125.00.
• On Wednesday, March 25th, Quiros Juan Jose Chacon sold 3,575 shares of Establishment Labs stock. The stock was sold at an average price of $60.08, for a total value of $214,786.00.
• On Monday, March 23rd, Quiros Juan Jose Chacon sold 33,925 shares of Establishment Labs stock. The stock was sold at an average price of $60.39, for a total value of $2,048,730.75.

Establishment Labs Price Performance

Establishment Labs stock opened at $62.43 on Thursday. The company has a debt-to-equity ratio of 10.51, a current ratio of 3.04 and a quick ratio of 2.00. The company has a market capitalization of $1.83 billion, a PE ratio of -35.88 and a beta of 1.08. Establishment Labs Holdings Inc. has a one year low of $29.36 and a one year high of $83.31. The business has a 50 day simple moving average of $65.68 and a 200 day simple moving average of $65.69.

Establishment Labs (NASDAQ:ESTA) last posted its earnings results on Tuesday, February 24th. The company reported ($0.09) EPS for the quarter, topping the consensus estimate of ($0.22) by $0.13. The business had revenue of $64.62 million during the quarter, compared to the consensus estimate of $63.80 million. Establishment Labs had a negative return on equity of 201.79% and a negative net margin of 24.19%.Establishment Labs’s revenue was up 45.2% on a year-over-year basis. During the same quarter last year, the company earned ($1.19) EPS. On average, sell-side analysts forecast that Establishment Labs Holdings Inc. will post -0.86 EPS for the current fiscal year.

Analysts Set New Price Targets

ESTA has been the subject of a number of recent analyst reports. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Establishment Labs in a report on Friday, March 27th. Canaccord Genuity Group raised their price target on Establishment Labs from $85.00 to $90.00 and gave the company a “buy” rating in a report on Thursday, February 26th. Mizuho raised their price target on Establishment Labs from $90.00 to $100.00 and gave the company an “outperform” rating in a report on Wednesday, February 25th. BTIG Research reaffirmed a “buy” rating and set a $88.00 price target on shares of Establishment Labs in a report on Wednesday. Finally, Stephens raised their price target on Establishment Labs from $85.00 to $90.00 and gave the company an “overweight” rating in a report on Wednesday, February 25th. Six investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $86.86.

Institutional Investors Weigh In On Establishment Labs

A number of institutional investors and hedge funds have recently made changes to their positions in the company. Geode Capital Management LLC raised its position in shares of Establishment Labs by 1.2% during the second quarter. Geode Capital Management LLC now owns 25,917 shares of the company’s stock worth $1,105,000 after acquiring an additional 299 shares during the last quarter. Brian Low Financial Group LLC raised its position in shares of Establishment Labs by 10.2% during the first quarter. Brian Low Financial Group LLC now owns 4,598 shares of the company’s stock worth $261,000 after acquiring an additional 424 shares during the last quarter. Handelsbanken Fonder AB raised its position in shares of Establishment Labs by 7.3% during the fourth quarter. Handelsbanken Fonder AB now owns 8,800 shares of the company’s stock worth $641,000 after acquiring an additional 600 shares during the last quarter. Swiss National Bank raised its position in shares of Establishment Labs by 1.8% during the fourth quarter. Swiss National Bank now owns 34,200 shares of the company’s stock worth $2,492,000 after acquiring an additional 600 shares during the last quarter. Finally, Kestra Advisory Services LLC bought a new stake in shares of Establishment Labs during the fourth quarter worth $47,000. Institutional investors own 72.91% of the company’s stock.

About Establishment Labs

Establishment Labs Holdings Inc is a global medical technology company specializing in the design, development and manufacture of silicone gel breast implants for aesthetic and reconstructive surgery. The company’s proprietary portfolio is built around patient-focused safety, customization and innovation, offering solutions intended to enhance surgical outcomes and support clinical traceability.

The company’s flagship products fall under the Motiva® brand, which includes a range of ergonomic and round breast implants featuring SilkSurface® texturing and an embedded Q Inside® Safety microtransponder for unique implant identification.